MSEK | 2020 | 2019 | 2018 | 2017 | 2016 |
Nettoomsättning | 414.4 | 379.9 | 357.2 | 329.2 | 311.6 |
Bruttoresultat | 209.8 | 196.4 | 181.3 | 146.6 | 158.7 |
Bruttomarginal | 50.6% | 51,7% | 50,7% | 44.5% | 50.9% |
EBITDA | 71.3 | 47.1 | 28.0 | 3.1 | 29.1 |
Resultat per aktie | 36.0 | -1.7 | -13.6 | -39.9 | -1.3 |
Kassaflöde frän lopande verksamhet |
37.2 | 9.2 | 17.9 | -59.6 | -33.1 |
Kassaflöde frän investeringsverksa Resultat per aktie |
-20.3 0.31 | -10.2 -0.04 | -13.9 -0.21 | -21.2 -0.52 | -21.8 -0.04 |
Eget kapital per aktie, SEK | 1.00 | 0.76 | 0.31 | 0.52 | 0.95 |
Soliditet | 21.6% | 16.7% | 6.1% | 10.0% | 20.6% |
Antal anstallda vid periodens slut |
118 | 120 | 116 | 119 | 108 |
Kontakta oss
Bluefish Pharmaceuticals AB
Gävlegatan 22
SE-113 30 Stockholm, Sweden
Tel: +46 8 5191 1600
Fax: +46 8 5191 1690
info-se@bluefishpharma.com
Viktiga kontakter
Affärsutveckling
business.development@bluefishpharma.com
Kundservice eller Rapportering biverkningar
drugreaction@bluefishpharma.com
Complaints
Tel +46 8 5191 1600
Fax +46 8 5191 1690
E-post complaints@bluefishpharma.com